Staurosporine (Synonyms: 星形孢菌素; Antibiotic AM-2282; STS; AM-2282)

目录号: HY-15141 纯度: 99.81%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Staurosporine 是一种有效，ATP 竞争性的，非选择性蛋白激酶抑制剂，抑制 PKC，PKA，c-Fgr，和 Phosphorylase kinase 的 IC₅₀ 分别为 6 nM，15 nM，2 nM，3 nM。Staurosporine 也抑制 TAOK2，IC₅₀ 值 3 μM。Staurosporine 是一个凋亡诱导剂。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Staurosporine Chemical Structure

CAS No. : 62996-74-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥1673	In-stock
2 mg	￥900	In-stock
5 mg	￥1630	In-stock
10 mg	￥2600	In-stock
50 mg		询价
100 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Staurosporine:

Staurosporine (GMP) In-stock
Staurosporine (Standard) 询价

MCE 顾客使用本产品发表的 126 篇科研文献

: Staurosporine purchased from MCE. Usage Cited in: Biochim Biophys Acta. 2018 Aug;1864(8):2600-2609. [Abstract]; Expression of Nogo-B and apoptosis-related proteins determined by Western blot analysis.

: Staurosporine purchased from MCE. Usage Cited in: Int Immunopharmacol. 2017 Sep;50:30-37. [Abstract]; BV-2 cells are pretreated with or without Staurosporine (1 μM) for 30 min, and then incubated with 20 μM Aβ_1–42 for 24 h. The protein expression of TNF-α, IL-1β, and IL-6 are detected by western blot.

: Staurosporine purchased from MCE. Usage Cited in: Neuroscience. 2017 Dec 4;365:217-225. [Abstract]; PMA markedly reduces the protein level of GLT-1.

: Staurosporine purchased from MCE. Usage Cited in: Cancer Res. 2013 Apr 15;73(8):2574-86. [Abstract]; Cells are treated with the indicated concentrations of AZD8055, Torin2 or staurosporin overnight and analyzed by western blot using antibodies specific for the indicated proteins.

Staurosporine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 PKC 亚型特异性产品:

查看所有亚型

PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKCι

查看 PKA 亚型特异性产品:

查看所有亚型

PKA PKAR

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC₅₀s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC₅₀ of 3 μM. Staurosporine is an apoptosis inducer^[1]^[2]^[3]^[4]^[5].

IC₅₀ & Target^[1]

PKC

6 nM (IC₅₀)

PKA

15 nM (IC₅₀)

c-Fgr

2 nM (IC₅₀)

Phosphorylase kinase

3 nM (IC₅₀)

S6 kinase (70 kDa)

5 nM (IC₅₀)

v-Src

6 nM (IC₅₀)

cdc2

9 nM (IC₅₀)

TPK-IIB/Syk

16 nM (IC₅₀)

Ca²⁺/CaM PK-I1

20 nM (IC₅₀)

MLCK

21 nM (IC₅₀)

61 nM (IC₅₀)

EGF-R

100 nM (IC₅₀)

ERK-1

1500 nM (IC₅₀)

CSK

2000 nM (IC₅₀)

IGF-IR

6150 nM (IC₅₀)

CK2

19500 nM (IC₅₀)

CK1

163500 nM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
518A2	EC₅₀	0.03 μM Compound: STS	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 29197730]
518A2	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24361521]
8505C	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24361521]
A2780	EC₅₀	0.1 μM Compound: Staurosporine	Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
A2780	IC₅₀	0.1 μM Compound: ST	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
A2780	EC₅₀	0.1 μM Compound: STS	Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
A2780	EC₅₀	0.12 μM Compound: STS	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 29197730]
A2780	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24361521]
A-375	IC₅₀	2.1 μM Compound: Staurosporine	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
A-431	IC₅₀	70 nM Compound: Staurosporine	Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay	[PMID: 22541051]
A549	IC₅₀	0.02 μM Compound: staurosporine	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25825934]
A549	IC₅₀	0.02 μM Compound: Staurosporine	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
A549	EC₅₀	0.04 μM Compound: STS	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 29197730]
A549	IC₅₀	0.6 μM Compound: STP	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24361521]
A549	IC₅₀	13.22 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31794211]
A549	IC₅₀	139.95 ng/mL Compound: Staurosporine	Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay	[PMID: 19138858]
A549	IC₅₀	139.95 ng/mL Compound: Staurosporine	Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay	[PMID: 19138858]
A549	GI₅₀	2.4 nM Compound: staurosporine	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method	[PMID: 18484775]
A549	IC₅₀	3.05 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells after 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 24 to 48 hrs by CCK-8 assay	[PMID: 24792811]
A549	IC₅₀	7.47 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells measured after 72 hrs under normoxic condition by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs under normoxic condition by MTT assay	[PMID: 31794211]
A549	IC₅₀	9.1 μM Compound: Staurosporine	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
A549	IC₅₀	9.5 μM Compound: Staurosporine	Cytotoxicity against human A549 cells assessed as cell viability measured by MTT assay Cytotoxicity against human A549 cells assessed as cell viability measured by MTT assay	[PMID: 34246754]
B16-F10	IC₅₀	2.82 μM Compound: Staurosporine	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 22503364]
BGC-823	IC₅₀	0.38 μM Compound: Staurosporine	Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
BGC-823	EC₅₀	26.83 μg/mL Compound: Staurosporine	Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay	[PMID: 21889345]
BGC-823	IC₅₀	6.83 μM Compound: Staurosporine	Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method	[PMID: 23018096]
BJ	EC₅₀	> 40 μM Compound: STS	Antiproliferative activity against human BJ cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human BJ cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
BJ	IC₅₀	0.002 μM Compound: Staurosporine	Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
BT-549	IC₅₀	0.08 μM Compound: Staurosporine	Cytotoxic activity against human BT549 cells incubated for 24 hrs by MTT assay Cytotoxic activity against human BT549 cells incubated for 24 hrs by MTT assay	[PMID: 28705432]
CAPAN-1	IC₅₀	0.0123 μM Compound: Staurosporine	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
CAPAN-1	IC₅₀	0.03 μM Compound: STS	Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
CAPAN-1	IC₅₀	0.0546 μM Compound: Staurosporine	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
Ca-Ski	IC₅₀	0.01144 μM Compound: Staurosporine	Antiproliferative activity against human Ca-Ski cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human Ca-Ski cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 34656041]
CCRF-CEM	IC₅₀	0.023 μM Compound: Staurosporine	Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
CHO-K1	GI₅₀	0.13 μM Compound: Staurosporine	Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay	[PMID: 21513294]
COLO 205	IC₅₀	< 0.1 μM Compound: Staurosporine	Antiproliferative activity against human COLO205 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human COLO205 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31740249]
DLD-1	IC₅₀	0.009 μM Compound: Staurosporine	Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay	[PMID: 22182929]
DLD-1	IC₅₀	0.009 μM Compound: Staurosporine	Antiproliferative activity against human colon cancer cell line (DLD-1 cells) using MTT assay Antiproliferative activity against human colon cancer cell line (DLD-1 cells) using MTT assay	[PMID: 11591505]
DU-145	IC₅₀	0.5 μM Compound: Staurosporine	Induction of mitochondrial membrane potential loss in human DU145 cells after 2 hrs by JC1 staining based fluorescence assay Induction of mitochondrial membrane potential loss in human DU145 cells after 2 hrs by JC1 staining based fluorescence assay	[PMID: 31120251]
FaDu	EC₅₀	0.1 μM Compound: Staurosporine	Cytotoxicity against human FaDu cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human FaDu cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
FaDu	IC₅₀	0.1 μM Compound: ST	Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
FaDu	EC₅₀	0.2 μM Compound: STS	Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
HaCaT	IC₅₀	1.6 μM Compound: Staurosporine	Antiproliferative activity against human HaCaT cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human HaCaT cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
HCT-116	IC₅₀	< 0.1 μM Compound: Staurosporine	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31740249]
HCT-116	IC₅₀	0.0281 μM Compound: Staurosporine	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
HCT-116	IC₅₀	0.03 μM Compound: Staurosporine	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30106291]
HCT-116	IC₅₀	0.04 μM Compound: STS	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
HCT-116	IC₅₀	0.0481 μM Compound: Staurosporine	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
HCT-116	IC₅₀	0.055 μM Compound: Staurosporine	Cytotoxicity against human HCT116 cells by sulforhodamine B assay Cytotoxicity against human HCT116 cells by sulforhodamine B assay	[PMID: 29389122]
HCT-116	IC₅₀	13.2 μM Compound: Staurosporine	Antiproliferative activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay Antiproliferative activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0306-5
HCT-116	IC₅₀	16.15 μM Compound: Staurosporine	Antiproliferative activity against human HCT116 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human HCT116 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31794211]
HCT-116	IC₅₀	39 nM Compound: Staurosporine	Inhibition of TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells by beta-lactamase reporter gene assay Inhibition of TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells by beta-lactamase reporter gene assay	[PMID: 23232060]
HCT-116	IC₅₀	6.94 μM Compound: Staurosporine	Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35694689]
HCT-116	IC₅₀	8.86 μM Compound: Staurosporine	Antiproliferative activity against human HCT116 cells measured after 72 hrs under normoxic condition by MTT assay Antiproliferative activity against human HCT116 cells measured after 72 hrs under normoxic condition by MTT assay	[PMID: 31794211]
HEK293	CC₅₀	0.00354 μM Compound: Staurosporine	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 72 hrs by CellTiter Glo luminescent assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 72 hrs by CellTiter Glo luminescent assay	[PMID: 28624701]
HEK293	IC₅₀	0.0037 μM Compound: Staurosporine	Cytotoxicity against human HEK293 cells assessed as cell viability incubated for 72 hrs by cell titer-glo luminescent cell viability assay (Rvb = > 100 uM) Cytotoxicity against human HEK293 cells assessed as cell viability incubated for 72 hrs by cell titer-glo luminescent cell viability assay (Rvb = > 100 uM)	[PMID: 31252285]
HEK293	IC₅₀	0.056 μM Compound: Staurosporine	Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay	[PMID: 24763262]
HEK293	IC₅₀	0.077 μM Compound: staurosporine	Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA	[PMID: 12941331]
HEK293	IC₅₀	0.077 μM Compound: Staurosporine	Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2 Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2	[PMID: 15771419]
HEK293	IC₅₀	0.41 μM Compound: Staurosporine	Antiproliferative activity against HEK293 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against HEK293 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
HEK293	IC₅₀	34.33 μM Compound: Staurosporine	Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability by MTT assay Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability by MTT assay	[PMID: 35182815]
HeLa	IC₅₀	0.025 μM Compound: staurosporine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25825934]
HeLa	IC₅₀	0.025 μM Compound: Staurosporine	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
HeLa	IC₅₀	0.175 μM Compound: Staurosporine	Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
HeLa	IC₅₀	2.72 μM Compound: Staurosporine	Antiproliferative activity against human HeLa cells after 24 to 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 24 to 48 hrs by CCK-8 assay	[PMID: 24792811]
HeLa	EC₅₀	29.12 μg/mL Compound: Staurosporine	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21889345]
HeLa	IC₅₀	4 pM Compound: Staurosporine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21488655]
HeLa	IC₅₀	4 pM Compound: Staurosporine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21388191]
HeLa	IC₅₀	9.12 μM Compound: Staurosporine	Antiproliferative activity against human HeLa cells after 48 hrs by MTT method Antiproliferative activity against human HeLa cells after 48 hrs by MTT method	[PMID: 23018096]
HeLa S3	IC₅₀	4 pM Compound: Staurosporine	Cytotoxicity against human HeLa S3 cells measured after 72 hrs Cytotoxicity against human HeLa S3 cells measured after 72 hrs	[PMID: 32688198]
HepG2	IC₅₀	0.018 μM Compound: Staurosporine	Cytotoxicity against human HepG2 cells at 100 uM after 3 days by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HepG2 cells at 100 uM after 3 days by CellTiter-Glo luminescent cell viability assay	[PMID: 28993106]
HepG2	EC₅₀	21.74 μg/mL Compound: Staurosporine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21889345]
HepG2	IC₅₀	4.14 μM Compound: Staurosporine	Inhibition of telomerase in human HepG2 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human HepG2 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 23018096]
HepG2	IC₅₀	6.73 μM Compound: Staurosporine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method	[PMID: 23018096]
HepG2	IC₅₀	8.3 μM Compound: Staurosporine	Inhibition of telomerase in human HepG2 cells after 48 hrs by TRAP-PCR-ELISA Inhibition of telomerase in human HepG2 cells after 48 hrs by TRAP-PCR-ELISA	[PMID: 23279864]
HepG2	IC₅₀	9.04 μM Compound: Staurosporine	Antiproliferative activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by MTT assay Antiproliferative activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0306-5
HL-60	IC₅₀	0.0076 μM Compound: Staurosporine	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
HL-60	IC₅₀	0.04 μM Compound: STS	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
HL-60	IC₅₀	0.041 μM Compound: Staurosporine	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
HMLE	IC₅₀	4.9 nM Compound: 1	Cytotoxicity against human HMLE cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay Cytotoxicity against human HMLE cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay	[PMID: 33335665]
HT-29	ED₅₀	> 20 μM Compound: Staurosporine	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 21973101]
HT-29	ED₅₀	0.0026 μM Compound: Staurosporine	Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay	[PMID: 21973101]
HT-29	EC₅₀	0.15 μM Compound: STS	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 29197730]
HT-29	EC₅₀	0.2 μM Compound: Staurosporine	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
HT-29	IC₅₀	0.2 μM Compound: ST	Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
HT-29	EC₅₀	0.2 μM Compound: STS	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
HT-29	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 24361521]
HT-29	GI₅₀	10.9 nM Compound: staurosporine	Cytotoxicity against human HT29 cells after 72 hrs by sulforhodamine B method Cytotoxicity against human HT29 cells after 72 hrs by sulforhodamine B method	[PMID: 18484775]
HT-29	IC₅₀	2 nM Compound: Staurosporine	Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay	[PMID: 21428375]
HT-29	IC₅₀	2.5 nM Compound: Staurosporine	Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay	[PMID: 21513293]
HT-29	ED₅₀	2.6 nM Compound: staurosporine	Induction of apoptosis in human HT-29 cells assessed as change in mitochondrial transmembrane potential after 2 hrs by JC1 staining based fluorescence assay Induction of apoptosis in human HT-29 cells assessed as change in mitochondrial transmembrane potential after 2 hrs by JC1 staining based fluorescence assay	[PMID: 19422206]
HT-29	IC₅₀	20 nM Compound: Staurosporine	Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay	[PMID: 30057155]
HT-29	GI₅₀	3.6 μM Compound: Staurosporine	Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 21513294]
Huh-7	IC₅₀	0.23 μM Compound: Staurosporine	Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
HUVEC	IC₅₀	0.004 μM Compound: Staurosporine	Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay	[PMID: 22182929]
HUVEC	IC₅₀	0.004 μM Compound: Staurosporine	Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay	[PMID: 11591505]
HUVEC	IC₅₀	0.5 μM Compound: STS	Cytotoxicity against HUVEC cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against HUVEC cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 34671737]
Jurkat	IC₅₀	0.0393 μM Compound: Staurosporine	Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
Jurkat	IC₅₀	0.14 μM Compound: Staurosporine	Cytotoxicity against human Jurkat cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human Jurkat cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
Jurkat	IC₅₀	3.2 μM Compound: Staurosporine	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
K562	IC₅₀	> 0.1 μM Compound: Staurosporine	Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
K562	IC₅₀	0.04 μM Compound: STS	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
K562	IC₅₀	0.0768 μM Compound: Staurosporine	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
K562	IC₅₀	1.7 μM Compound: Staurosporine	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30106291]
K562	IC₅₀	153 μM Compound: STSP	Antitumor activity against human K562 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antitumor activity against human K562 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26022079]
KB 3-1	IC₅₀	< 0.2 μM Compound: Staurosporine	Antiproliferative activity against human KB-3-1 cells after 5 days by WST-1 assay Antiproliferative activity against human KB-3-1 cells after 5 days by WST-1 assay	[PMID: 28956915]
KOPN-8	EC₅₀	0.71 μM Compound: STS	Antiproliferative activity against human KOPN8 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human KOPN8 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
L02	IC₅₀	9.5 μM Compound: Staurosporine	Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30106291]
L929	IC₅₀	< 0.2 μM Compound: Staurosporine	Antiproliferative activity against mouse L929 cells after 5 days by WST-1 assay Antiproliferative activity against mouse L929 cells after 5 days by WST-1 assay	[PMID: 28956915]
Leukemia cell	EC₅₀	0.35 μM Compound: STS	Antiproliferative activity against mouse leukemia cells overexpressing BCR/ABL after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against mouse leukemia cells overexpressing BCR/ABL after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
LN-229	IC₅₀	0.003 μM Compound: STS	Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
LN-229	IC₅₀	0.0097 μM Compound: Staurosporine	Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
LoVo	IC₅₀	0.001 μM Compound: Staurosporine	Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay	[PMID: 22182929]
LoVo	IC₅₀	0.001 μM Compound: Staurosporine	Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay	[PMID: 11591505]
LOX IMVI	IC₅₀	7.15 μM Compound: Staurosporine	Cytotoxicity against human LOX IMVI cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human LOX IMVI cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33601311]
MCF7	IC₅₀	0.013 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	10.1039/C2MD20098H
MCF7	IC₅₀	0.064 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
MCF7	EC₅₀	0.1 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
MCF7	IC₅₀	0.1 μM Compound: ST	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
MCF7	EC₅₀	0.1 μM Compound: STS	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
MCF7	EC₅₀	0.1 μM Compound: STS	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 29197730]
MCF7	IC₅₀	0.33 μM Compound: Staurosporine	Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA	[PMID: 31992477]
MCF7	IC₅₀	0.4 μM Compound: STP	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 24361521]
MCF7	IC₅₀	0.52 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay Cytotoxicity against human MCF7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay	[PMID: 24328283]
MCF7	IC₅₀	1.8 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells after 5 days by WST-1 assay Antiproliferative activity against human MCF7 cells after 5 days by WST-1 assay	[PMID: 28956915]
MCF7	GI₅₀	11 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 21513294]
MCF7	IC₅₀	16.06 μM Compound: Staurosporine	Antiproliferative activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay Antiproliferative activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0306-5
MCF7	IC₅₀	180 nM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay	[PMID: 22541051]
MCF7	IC₅₀	2 μM Compound: Staurosporine	Inhibition of PKA in human MCF7 cells by array-based fluorescence assay Inhibition of PKA in human MCF7 cells by array-based fluorescence assay	[PMID: 18656369]
MCF7	IC₅₀	3.07 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22503364]
MCF7	IC₅₀	3.39 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxic condition by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxic condition by MTT assay	[PMID: 31972394]
MCF7	IC₅₀	3.67 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay	[PMID: 33667848]
MCF7	IC₅₀	3.67 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay	[PMID: 32877804]
MCF7	IC₅₀	4.1 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34482273]
MCF7	IC₅₀	4.1 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34871842]
MCF7	IC₅₀	50 nM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21488655]
MCF7	IC₅₀	50 nM Compound: Staurosporine	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21388191]
MCF7	IC₅₀	6.08 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay	[PMID: 34743062]
MCF7	IC₅₀	6.3 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay	[PMID: 35196017]
MCF7	IC₅₀	7.25 μM Compound: Staurosporine	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35694689]
MCF7	IC₅₀	7.33 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay	[PMID: 32877804]
MCF7	IC₅₀	8.81 μM Compound: Staurosporine	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by MTT assay	[PMID: 31992477]
MCF7	IC₅₀	9.2 μM Compound: Staurosporine	Antiproliferative activity against human MCF7 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31972394]
MDA-MB-231	IC₅₀	0.0008581 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 34656041]
MDA-MB-231	IC₅₀	0.01 μM Compound: Staurosporin	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.24 μM Compound: Staurosporine	Cytotoxic activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay Cytotoxic activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay	[PMID: 28705432]
MDA-MB-231	IC₅₀	2.5 nM Compound: 1	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay	[PMID: 33335665]
MDA-MB-231	IC₅₀	4.25 μM Compound: Staurosporine	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay	[PMID: 32044580]
MDA-MB-231	IC₅₀	4.31 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay	[PMID: 32877804]
MDA-MB-231	IC₅₀	6.75 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells incubated for 2 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 2 days by MTT assay	[PMID: 33667848]
MDA-MB-231	IC₅₀	6.75 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay	[PMID: 32877804]
MDA-MB-231	GI₅₀	7.1 nM Compound: staurosporine	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method	[PMID: 18484775]
MDA-MB-453	IC₅₀	0.02351 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 34656041]
MDA-MB-468	IC₅₀	0.15 μM Compound: Staurosporine	Cytotoxic activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay Cytotoxic activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay	[PMID: 28705432]
MDA-MB-468	IC₅₀	4.37 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under normoxic condition by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under normoxic condition by MTT assay	[PMID: 31972394]
MDA-MB-468	IC₅₀	6.46 μM Compound: Staurosporine	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31972394]
MGC-803	IC₅₀	8.97 μM Compound: Staurosporine	Inhibition of telomerase in human MGC-803 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human MGC-803 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 26900656]
MIA PaCa-2	IC₅₀	370 nM Compound: Staurosporine	Antiproliferative activity against MiaPaCa-2 cells by MTT assay Antiproliferative activity against MiaPaCa-2 cells by MTT assay	[PMID: 16403626]
MM1.S	IC₅₀	0.0442 μM Compound: Staurosporine	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
MV4-11	IC₅₀	0.05 μM Compound: Staurosporine	Cytotoxicity against human MV4-11cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Cytotoxicity against human MV4-11cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
N2a	IC₅₀	0.0113 μM Compound: Staurosporine	Cytotoxicity against mouse Neuro2a cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against mouse Neuro2a cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 28152427]
NALM-6	EC₅₀	1.4 μM Compound: STS	Antiproliferative activity against human NALM6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human NALM6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
NCI-H460	IC₅₀	> 0.1 μM Compound: Staurosporine	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
NCI-H460	IC₅₀	0.0597 μM Compound: Staurosporine	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
NCI-H460	IC₅₀	0.06 μM Compound: STS	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
NCI-H460	GI₅₀	3.6 μM Compound: Staurosporine	Cytotoxicity against human H460 cells after 48 hrs by SRB assay Cytotoxicity against human H460 cells after 48 hrs by SRB assay	[PMID: 21513294]
NIH3T3	EC₅₀	0.008 μM Compound: Staurosporine	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
NIH3T3	IC₅₀	0.008 μM Compound: ST	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
NIH3T3	EC₅₀	0.008 μM Compound: STS	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
NIH3T3	EC₅₀	0.008 μM Compound: STS	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 29197730]
NIH3T3	IC₅₀	0.2 μM Compound: STP	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24361521]
NIH3T3	IC₅₀	140.12 μM Compound: Staurosporine	Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay	[PMID: 24286761]
PBMC	IC₅₀	0.0002 μM Compound: Staurosporine	Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay	[PMID: 33248847]
PBMC	IC₅₀	0.016 μM Compound: staurosporine	Inhibition of IL2 production in PHA-stimulated human PBMC after 24 hrs by ELISA Inhibition of IL2 production in PHA-stimulated human PBMC after 24 hrs by ELISA	[PMID: 18823784]
PBMC	IC₅₀	0.016 μM Compound: 1	Suppression of IL2 production in human PBMC after 24 hrs by ELISA Suppression of IL2 production in human PBMC after 24 hrs by ELISA	[PMID: 18585046]
PC-3	IC₅₀	0.017 μM Compound: Staurosporine	Cytotoxicity against human PC3 cells by sulforhodamine B assay Cytotoxicity against human PC3 cells by sulforhodamine B assay	[PMID: 29389122]
PC-3	IC₅₀	0.031 μM Compound: staurosporine	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25825934]
PC-3	IC₅₀	0.039 μM Compound: STU	Cytotoxicity against human PC3 cells after 72 hrs by SRB assay Cytotoxicity against human PC3 cells after 72 hrs by SRB assay	[PMID: 29558119]
PC-3	IC₅₀	4.91 μM Compound: Staurosporine	Antiproliferative activity against human PC3 cells measured after 72 hrs under normoxic condition by MTT assay Antiproliferative activity against human PC3 cells measured after 72 hrs under normoxic condition by MTT assay	[PMID: 31794211]
PC-3	IC₅₀	5.92 μM Compound: Staurosporine	Antiproliferative activity against human PC3 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay Antiproliferative activity against human PC3 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay	[PMID: 31794211]
RBL-2H3	IC₅₀	0.2 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced IL-4 level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced IL-4 level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	0.3 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced TNF-alpha level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced TNF-alpha level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	0.3 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of mouse anti-DNP IgE-stimulated beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-bet Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of mouse anti-DNP IgE-stimulated beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-bet	[PMID: 31879206]
RBL-2H3	IC₅₀	0.3 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-be Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-be	[PMID: 30711393]
RBL-2H3	IC₅₀	0.5 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of anti-DNP IgE-stimulated TNFalpha release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by ELISA Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of anti-DNP IgE-stimulated TNFalpha release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by ELISA	[PMID: 31879206]
RBL-2H3	IC₅₀	0.7 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced IL-4 level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced IL-4 level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	0.8 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated beta-hexosaminidase release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated beta-hexosaminidase release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside	[PMID: 31879206]
RBL-2H3	IC₅₀	1 μM Compound: Staurosporine	Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated TNFalpha release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by ELISA Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated TNFalpha release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by ELISA	[PMID: 31879206]
RBL-2H3	IC₅₀	1 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced TNF-alpha level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced TNF-alpha level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA	[PMID: 30711393]
RBL-2H3	IC₅₀	1 μM Compound: Staurosporine	Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced beta-hexosaminidase release preincubated for 15 mins followed by calcium ionophore-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced beta-hexosaminidase release preincubated for 15 mins followed by calcium ionophore-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta	[PMID: 30711393]
Rec1	IC₅₀	0.0255 μM Compound: Staurosporine	Cytotoxicity against human REC1 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Cytotoxicity against human REC1 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
Sf21	IC₅₀	0.002 μM Compound: Staurosporine	Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method	[PMID: 27137359]
Sf21	IC₅₀	0.027 μM Compound: staurosporine	Inhibition of human CHK2 kinase expressed in insect Sf21 cells using phospho-CREBtide as substrate at 30 uM Inhibition of human CHK2 kinase expressed in insect Sf21 cells using phospho-CREBtide as substrate at 30 uM	[PMID: 21334796]
Sf21	IC₅₀	0.039 μM Compound: staurosporine	Inhibition of human recombinant IKK-alpha expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM Inhibition of human recombinant IKK-alpha expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM	[PMID: 21334796]
Sf21	IC₅₀	0.49 μM Compound: staurosporine	Inhibition of human recombinant IKK-beta expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM Inhibition of human recombinant IKK-beta expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM	[PMID: 21334796]
Sf21	IC₅₀	1325 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 5 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 5 mins by time resolved-fluorescent assay	[PMID: 21441024]
Sf21	IC₅₀	1533 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 30 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 30 mins by time resolved-fluorescent assay	[PMID: 21441024]
Sf21	IC₅₀	1646 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 60 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 60 mins by time resolved-fluorescent assay	[PMID: 21441024]
Sf21	IC₅₀	1701 nM Compound: Staurosporine	Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 10 mins by time resolved-fluorescent assay Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 10 mins by time resolved-fluorescent assay	[PMID: 21441024]
SF-268	GI₅₀	0.044 μM Compound: Staurosporine	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 21513294]
Sf9	IC₅₀	> 18.5 μM Compound: Staurosporine	Inhibition of human recombinant ALK5 expressed in insect Sf9 cells using casein as substrate by radioisotopic assay Inhibition of human recombinant ALK5 expressed in insect Sf9 cells using casein as substrate by radioisotopic assay	[PMID: 24786585]
Sf9	IC₅₀	0.0039 μM Compound: Staurosporine	Inhibition of N-terminal His-tagged recombinant human AXL (473 to end amino acids) expressed by baculovirus in Sf9 cells using axltide substrate and ATP by ADP-Glo luminescence assay Inhibition of N-terminal His-tagged recombinant human AXL (473 to end amino acids) expressed by baculovirus in Sf9 cells using axltide substrate and ATP by ADP-Glo luminescence assay	[PMID: 30340900]
Sf9	IC₅₀	0.005 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.015 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.036 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.083 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.27 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	0.51 μM Compound: Staurosporine	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP	[PMID: 17315853]
Sf9	IC₅₀	1.2 nM Compound: Staurosporine	Inhibition of N-terminal GST tagged recombinant full-length human CHK1 expressed in baculovirus Sf9 insect cells after 10 mins by luminescent ADP-Glo assay Inhibition of N-terminal GST tagged recombinant full-length human CHK1 expressed in baculovirus Sf9 insect cells after 10 mins by luminescent ADP-Glo assay	[PMID: 27089211]
Sf9	IC₅₀	2.3 μM Compound: staurosporine	Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay	[PMID: 20580552]
ST486	IC₅₀	0.007 μM Compound: Staurosporine	Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay	[PMID: 22182929]
SUP-B15	EC₅₀	0.55 μM Compound: STS	Antiproliferative activity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
SW 1116	EC₅₀	24.92 μg/mL Compound: Staurosporine	Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay	[PMID: 21889345]
SW 1116	IC₅₀	4.18 μM Compound: Staurosporine	Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 24286761]
SW 1116	IC₅₀	4.95 μM Compound: Staurosporine	Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method	[PMID: 23018096]
SW 1116	IC₅₀	8.32 μM Compound: Staurosporine	Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay	[PMID: 21962523]
SW-1736	EC₅₀	0.2 μM Compound: STS	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
SW480	IC₅₀	< 0.1 μM Compound: Staurosporine	Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31740249]
T47D	IC₅₀	11.7 μM Compound: Staurosporine	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 3 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 3 hrs by MTT assay	[PMID: 33962153]
T47D	IC₅₀	4.52 μM Compound: Staurosporine	Cytotoxicity against human T47D cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay Cytotoxicity against human T47D cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay	[PMID: 32044580]
TERT-RPE1	IC₅₀	0.0055 μM Compound: Staurosporine	Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis	[PMID: 33248847]
UoC-B1	EC₅₀	2 μM Compound: STS	Antiproliferative activity against human UOCB1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human UOCB1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30840453]
Vero	IC₅₀	0.0024 μM Compound: Staurosporine	Cytotoxicity against African green monkey Vero cells after 2 days by CellTiter-Glo luminescent cell viability assay Cytotoxicity against African green monkey Vero cells after 2 days by CellTiter-Glo luminescent cell viability assay	[PMID: 28993106]
Vero	IC₅₀	0.028 μM Compound: Staurosporine	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30743094]
WI-38	IC₅₀	24.41 μM Compound: Staurosporine	Cytotoxicity against human WI-38 cells assessed as cell viability measured by MTT assay Cytotoxicity against human WI-38 cells assessed as cell viability measured by MTT assay	[PMID: 34246754]
Z-138	IC₅₀	0.0067 μM Compound: Staurosporine	Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	[PMID: 33248847]
Z-138	IC₅₀	0.02 μM Compound: STS	Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	[PMID: 32832030]
Z-138	IC₅₀	0.0418 μM Compound: Staurosporine	Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]

体外研究
(In Vitro)

Staurosporine 是一种能够从 Streptomyces staurospores 培养液中分离出来的生物碱，广泛用作蛋白激酶 C (PKC) 抑制剂，具有广谱活性。MC3T3E-1 成骨细胞暴露于 Staurosporine (100 nM) 12 小时后，释放出与对照细胞 (10.0±2.4%) 相似的 LDH 量 (12.4±3.1%)，表明相对缺乏裂解细胞死亡，发生在坏死。此外，用 Staurosporine (100 nM) 处理会导致形态学变化，这是细胞凋亡的特征：在 Hoechst 33258 染色后通过荧光显微镜观察到亮蓝色荧光浓缩核，细胞体积减小^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Staurosporine 的抑制作用在肿瘤促进的第 10 周左右具有统计学意义。尽管在实验的后几周使用 10 ng Staurosporine 没有获得统计学上显著的抑制作用，但荷瘤小鼠的百分比和每只小鼠的平均肿瘤数明显呈下降趋势。因此，即使在 Staurosporine 本身诱导肿瘤的剂量下，Staurosporine 也会轻微抑制 Teleocidin 的肿瘤促进作用^[3]。Staurosponne (0.05 和 0.1 mg/kg 腹膜内注射) 可减轻水迷宫和被动回避任务的受损性能，即使给药是在损伤后 2 周开始的。此外，Staurosporine (0.1 mg/kg) 部分逆转了由基底前脑损伤引起的额顶叶皮层中胆碱乙酰转移酶活性的降低。这些结果表明 Staurosporine 通过逆转由基底前脑损伤引起的胆碱能神经元损伤来减轻学习障碍^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

466.53

Formula

C₂₈H₂₆N₄O₃

CAS 号

62996-74-1

性状

固体

颜色

White to yellow

中文名称

星形孢菌素

结构分类

初始来源

微生物

Streptomyces staurosporeus

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : 62.5 mg/mL (133.97 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1435 mL	10.7174 mL	21.4348 mL
5 mM	0.4287 mL	2.1435 mL	4.2870 mL
10 mM	0.2143 mL	1.0717 mL	2.1435 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.46 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.46 mM); 悬浊液; 超声助溶

此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.46 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 3.33 mg/mL (7.14 mM); Suspension solution; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.98%

选择批次：

Data Sheet (677 KB) SDS (418 KB)

COA (299 KB) HNMR (185 KB) LCMS (603 KB) 元素分析报告 (222 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Meggio F, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem. 1995 Nov 15;234(1):317-22. [Content Brief]

[2]. Chae HJ, et al. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res. 2000 Oct;42(4):373-81. [Content Brief]

[3]. Yoshizawa S, et al. Tumor-promoting activity of staurosporine, a protein kinase inhibitor on mouse skin.Cancer Res. 1990 Aug 15;50(16):4974-8. [Content Brief]

[4]. Nabeshima T, et al. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J Pharmacol Exp Ther. 1991 May;257(2):562-6. [Content Brief]

[5]. Yujie Ren, et al. The ORF3a Protein of SARS-CoV-2 Induces Apoptosis in Cells. Cell Mol Immunol. 2020 Jun 18;1-3. [Content Brief]

Animal Administration ^[3]^[4]	Mice^[3] Female CD-I mice are used. Various amounts of Staurosporine in 10 μL of acetone are applied to the ears of 8-wk-old CD-I mice. The extent of irritation is expressed as the minimum dose of the compound causing irritation. Induction of HOC in Mouse Skin Staurosporine in 0.1 mL of acetone is applied to the skin of the backs of CD-I mice, and a crude enzyme extract is obtained from the skin 18 h later. HDC activity is expressed as pmol of CO₂ released per mg of protein per l h of incubation. Induction of ODC in Mouse Skin Staurosporine in 0.2 mL of acetone is applied to the skin of the backs of CD-I mice. After 4 h, a crude enzyme extract is prepared from the epidermis, and its ODC activity is measured. Enzyme activity is expressed as nmol of CO₂ per mg of protein per 30 min of incubation. Rats^[4] Male Kbl Wistar rats(weighing 270 to 310 g) are used. In the group which is given Staurosporine for 2 weeks, the water maze task and Staurosporine administration are started 2 weeks after the BF-lesion, and the passive avoidance task is carried out 4 weeks after the BFlesion. The rat received Staurosporine at doses of 0.01, 0.03, 0.1, and 0.3 mg/kg (i.p., N=10 in each group for 2 weeks) 30 mm prior to the water maze training sessions and the passive avoidance task acquisitiontrial. In the group which is given Staurosporine for 4 weeks, the drug is first given 2 weeks after the BF-lesion. The water maze task is carried out 4 weeks after the BF-lesion. The passive avoidance task is carried out 6 weeks after the BF-lesion. The rat received Staurosporine at 0.05, 0.1, and 0.2 mg/kg (i.p., N=10 in each group) once a day for 2 weeks before training, and for 2 weeks after the water maze training sessions and the passive avoidance task acquisition trial. Staurosporine is suspended in 0.3% of sodium carboxymethyl cellulose. The vehicle is administered to the non-lesioned controls and the lesioned controls on the same schedule as the Staurosporine-treated animals. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Meggio F, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem. 1995 Nov 15;234(1):317-22. [Content Brief] [2]. Chae HJ, et al. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res. 2000 Oct;42(4):373-81. [Content Brief] [3]. Yoshizawa S, et al. Tumor-promoting activity of staurosporine, a protein kinase inhibitor on mouse skin.Cancer Res. 1990 Aug 15;50(16):4974-8. [Content Brief] [4]. Nabeshima T, et al. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J Pharmacol Exp Ther. 1991 May;257(2):562-6. [Content Brief] [5]. Yujie Ren, et al. The ORF3a Protein of SARS-CoV-2 Induces Apoptosis in Cells. Cell Mol Immunol. 2020 Jun 18;1-3. [Content Brief]

Animal Administration
^[3]^[4]

Mice^[3]
Female CD-I mice are used. Various amounts of Staurosporine in 10 μL of acetone are applied to the ears of 8-wk-old CD-I mice. The extent of irritation is expressed as the minimum dose of the compound causing irritation. Induction of HOC in Mouse Skin Staurosporine in 0.1 mL of acetone is applied to the skin of the backs of CD-I mice, and a crude enzyme extract is obtained from the skin 18 h later. HDC activity is expressed as pmol of CO₂ released per mg of protein per l h of incubation. Induction of ODC in Mouse Skin Staurosporine in 0.2 mL of acetone is applied to the skin of the backs of CD-I mice. After 4 h, a crude enzyme extract is prepared from the epidermis, and its ODC activity is measured. Enzyme activity is expressed as nmol of CO₂ per mg of protein per 30 min of incubation.
Rats^[4]
Male Kbl Wistar rats(weighing 270 to 310 g) are used. In the group which is given Staurosporine for 2 weeks, the water maze task and Staurosporine administration are started 2 weeks after the BF-lesion, and the passive avoidance task is carried out 4 weeks after the BFlesion. The rat received Staurosporine at doses of 0.01, 0.03, 0.1, and 0.3 mg/kg (i.p., N=10 in each group for 2 weeks) 30 mm prior to the water maze training sessions and the passive avoidance task acquisitiontrial. In the group which is given Staurosporine for 4 weeks, the drug is first given 2 weeks after the BF-lesion. The water maze task is carried out 4 weeks after the BF-lesion. The passive avoidance task is carried out 6 weeks after the BF-lesion. The rat received Staurosporine at 0.05, 0.1, and 0.2 mg/kg (i.p., N=10 in each group) once a day for 2 weeks before training, and for 2 weeks after the water maze training sessions and the passive avoidance task acquisition trial. Staurosporine is suspended in 0.3% of sodium carboxymethyl cellulose. The vehicle is administered to the non-lesioned controls and the lesioned controls on the same schedule as the Staurosporine-treated animals.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Meggio F, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem. 1995 Nov 15;234(1):317-22. [Content Brief]

[2]. Chae HJ, et al. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res. 2000 Oct;42(4):373-81. [Content Brief]

[3]. Yoshizawa S, et al. Tumor-promoting activity of staurosporine, a protein kinase inhibitor on mouse skin.Cancer Res. 1990 Aug 15;50(16):4974-8. [Content Brief]

[4]. Nabeshima T, et al. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J Pharmacol Exp Ther. 1991 May;257(2):562-6. [Content Brief]

[5]. Yujie Ren, et al. The ORF3a Protein of SARS-CoV-2 Induces Apoptosis in Cells. Cell Mol Immunol. 2020 Jun 18;1-3. [Content Brief]

Staurosporine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1435 mL	10.7174 mL	21.4348 mL	53.5871 mL
	5 mM	0.4287 mL	2.1435 mL	4.2870 mL	10.7174 mL
	10 mM	0.2143 mL	1.0717 mL	2.1435 mL	5.3587 mL
	15 mM	0.1429 mL	0.7145 mL	1.4290 mL	3.5725 mL
	20 mM	0.1072 mL	0.5359 mL	1.0717 mL	2.6794 mL
	25 mM	0.0857 mL	0.4287 mL	0.8574 mL	2.1435 mL
	30 mM	0.0714 mL	0.3572 mL	0.7145 mL	1.7862 mL
	40 mM	0.0536 mL	0.2679 mL	0.5359 mL	1.3397 mL
	50 mM	0.0429 mL	0.2143 mL	0.4287 mL	1.0717 mL
	60 mM	0.0357 mL	0.1786 mL	0.3572 mL	0.8931 mL
	80 mM	0.0268 mL	0.1340 mL	0.2679 mL	0.6698 mL
	100 mM	0.0214 mL	0.1072 mL	0.2143 mL	0.5359 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Staurosporine (Synonyms: 星形孢菌素; Antibiotic AM-2282; STS; AM-2282)

Customer Review

Other Forms of Staurosporine:

MCE 顾客使用本产品发表的 126 篇科研文献

Staurosporine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 PKC 亚型特异性产品:

查看 PKA 亚型特异性产品:

查看 Antibiotic 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Staurosporine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Staurosporine (Synonyms: 星形孢菌素; Antibiotic AM-2282; STS; AM-2282)

Customer Review

Other Forms of Staurosporine:

Staurosporine 相关抗体

MCE 顾客使用本产品发表的 126 篇科研文献

Staurosporine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 PKC 亚型特异性产品:

查看 PKA 亚型特异性产品:

查看 Antibiotic 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Staurosporine 相关抗体:

摩尔计算器

稀释计算器

Staurosporine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z